What is the source of monoclonal antibodies ending in "-omab"?

Monoclonal antibodies that end in "-omab" are derived from murine (mouse) sources. This nomenclature indicates that they are completely mouse-derived antibodies, which are developed by injecting mice with specific antigens to elicit an immune response. The resulting antibodies are harvested from the spleen of the immunized mice, leading to the creation of monoclonal antibodies that are entirely of mouse origin.

While other types of antibodies such as human, chimeric (human-mouse), and humanized antibodies have diverse applications in therapeutics, the use of the suffix "-omab" specifically denotes a fully murine origin. This is important to understand, as the immunogenicity of murine antibodies can lead to different responses in human patients compared to human or humanized counterparts. This distinction plays a crucial role in their therapeutic effectiveness and potential side effects in cancer treatment protocols.